CAJ | 학술논문

自身免疫性甲状腺疾病( AITD)是一组有相似遗传和免疫背景但临床表现迥异的疾病.促甲状腺激素受体抗体对Graves病(GD)和Graves眼病(GO)的诊断及预后判断有重要意义.甲状腺过氧化物酶抗体(TPOAb)和甲状腺球蛋白抗体是自身免疫性甲状腺炎(AIT)的标志性抗体.GD的治疗仍以控制甲状腺功能亢进症为主,重度GO则需免疫抑制治疗.硒治疗是目前有循证医学证据的降低AIT患者TPOAb水平的方法.针对AITD病因的免疫治疗仍有待开发及循证医学证据支持.
자신면역성갑상선질병( AITD)시일조유상사유전화면역배경단림상표현형이적질병.촉갑상선격소수체항체대Graves병(GD)화Graves안병(GO)적진단급예후판단유중요의의.갑상선과양화물매항체(TPOAb)화갑상선구단백항체시자신면역성갑상선염(AIT)적표지성항체.GD적치료잉이공제갑상선공능항진증위주,중도GO칙수면역억제치료.서치료시목전유순증의학증거적강저AIT환자TPOAb수평적방법.침대AITD병인적면역치료잉유대개발급순증의학증거지지.
Autoimmune thyroid diseases (AITD) are a group of diseases with significant different clinical manifestation,but with similar genetic and immunologic background.Thyrotropin receptor antibody (TRAb) has significance in the diagnosis and prediction of prognosis for Graves' disease (GD) and Graves'ophthalmopathy (GO).Anti-thyroperoxidase antibody (TPOAb) and anti-thyroglobulin antibody are hallmark of autoimmune thyroiditis (AIT).The therapies for GD are mainly to control the hyperthyroidism.Immunosuppressive therapy is used for sever GO.Up to date,evidence-based medical evidence has demonstrated that treatment using selenium could decrease the level of TPOAb in the patients with AIT.The immune therapies to the pathogenesis of AITD still need to be developed and supported by clinical evidence.